[1]
Hauptman J.S.. Mathern G.W.: Surgical treatment of epilepsy associated
with crtical dyslasia: 2012 update. Epilepsia 2012; 53: 98–104.
[2]
Taylor D.C., Falconer M.A., Bruton C.J., et al.: Focal dysplasia of the
cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry 1971; 34:
369–387.
[3]
Leach J.L., Greiner H.M., Miles L. et al.: Imaging Spectrum of Cortical
Dysplasia in Children. Semin. Roentgenol. 2014; 49: 99–111.
[4]
Műhlebner A., Grőppel G., Dressler A., et al.: Epilepsy surgery in children
and adolescents with malformations of cortical development – Outcome
and impact of the new ILAE classification on focal cortical dysplasia.
Epilepsy Res. 2014; 108: 1652–1661.
[5]
Blűmcke I., Thom M., Aronica E., et al.: The clinicopathologic spectrum
of focal cortical dysplasias: A consensus classification proposed by an
ad hoc Task Force. Epilepsia 2011; 52: 158–174.
[6]
Tassi L., Garbelli R., Colombo N.: Type I focal cortical dysplasia: surgical
outcome is related to histopathology. Epileptic Disord 2010; 3: 181–191.
[7]
Fauser S., Essang C., Altenmuller D.M.: Long-term seizure outcome in
211 patiens with focal cortical dysplasia. Epilepsia 2015; 56: 66–76.
[8]
Sisodiya S.M., Fauser S., Cross J.H., et al.: Focal cortical dysplasia type
II: biological features and clinical perspectives. Lancet Neurol 2009; 8:
830–843.
[9]
Blűmcke I., Sarnat H.B.: Somatic mutations rather than viral infection
classify focal cortical dysplasia type II as mTORopathy. Curr Opin Neurol
2016; 29: 388–396.
[10]
Lerner J.T., Salomon N., Hauptman J.S.; Assessment and surgical
outcomes for mild type I and severe type II cortical dysplasia: A critical
review and the UCLA experience. Epilepsia 2009; 50: 1310–1335.
[11]
Bartolini L., Whitehead M., Ho C.: Temporal lobe epilepsy and focal
cortical dysplasia in children: A tip to find the abnormality. Epilepsia
2017; 58: 113–122.
[12]
Krsek P., Maton B., Jayakar P.: Incomplete resection of focal cortical
dysplasia is the main predictor of poor postsurgical outcome. Neurology
2009; 72: 217–223.
[13]
Sacino M.F., Ho C.Y., Whitehead M.T.: Repeat surgery for focal cortical
dysplasias in children. J Neurosurg Pediatr 2017; 19: 174–181.
[14]
Kim Y.H., Kang H.C., Kim D.K.: Neuroimaging in identifying focal cortical
dysplasia and prognostic factors in pediatric and adolescent epilepsy
surgery. Epilepsia 2011; 52: 722–727.
[15]
Fauser S., Essang C., Altenmuller D.M.: Is there evidence for clinical
differences related t the new classification of temporal lobe cortical
dysplasia? Epilepsia 2013; 54: 909–917.
[16]
Fauser S., Sisodiya S.M., Martinian L., et al.: Multi-focal occurrence of
cortical dysplasia in epilepsy patients. Brain 2009; 132: 2079–2090.
[17]
Maynard L.M., Leach J.L., Horn P.S., et al.: Epilepsy prevalence and
severity predictors in MRI-identified focal cortical dysplasia. Epilepsy
Res 2017; 132: 41–49.
[18]
Xue H., Cai L., Dong S., et al.: Clinical characteristics and post-surgical
outcomes of focal cortical dysplasia subtypes. J Clin Nerosc 2016; 23:
68–72.
[19]
Guerrini R., Duchowny M., Jayakar P.: Diagnostic methods and treatment
options for focal cortical dysplasia. Epilepsia 2015; 56: 1669–1686.
[20]
Becker A.J., Urbach H., Scheffler B., et al.: Focal cortical dysplasia of
Taylor’s balloon cell type: mutational analysis of the TSC1 gene indicates
a pathogenic relationship to tuberous sclerosis. Ann Neurol 2002; 52:
29–37.
[21]
Nakashima M., Saitsu H., Takei N.: Somatic Mutations in the MTOR
Gene Cause Focal Cortical Dysplasia Type IIb. Ann Naurol 2015; 78:
375–386.
[22]
Galanopoulou A.S., Gorter J.A., Cepeda C.: Finding a better drug for
epilepsy: The mTOR pathway as an antiepileptogenic target. Epilepsia
2012; 53: 1119–1130.
[23]
Chen J., Tsai V., Parker W.E., et al.: Detection of human papillomavirus in
human focal cortical dysplasia type IIB. Ann Neurol 2012; 72: 881–892.
[24]
Liu S., Lu L., Cheng X., et al.: Viral infection and focal cortical dysplasia.
Ann Neurol 2014; 75: 614–616.
[25]
Antuono M., Louvel J., Kohling R., et al.: GABA A receptor-dependent
synchronization leads to ictogenesis in the human dysplastic cortex.
Brain 2004; 127: 1626–1640.
[26]
Cepeda C., Andre V.M., Flores-Hernandez J., et al.: Pediatric cortical
dysplasia: correlations between neuroimaging, electrophysiology and
location of cytomegalic neurons and balloon cells and glutamate/GABA
synaptic circuits. Dev Neurosci 2005; 27: 59–76.
[27]
Radhakrishnan R., Leach J., Mangano F., et al.: Prospective detection of
cortical dysplasia on clinical MRI in pediatric intractable epilepsy. Pediatr
Radiol 2016; 10: 1430–1438.
[28]
Barkovich A., Kuzniecky R., Bollen A., et al.: Focal transmantle dysplasia:
a specific malformation of cortical development. Neurology 1997; 49:
1148–1152.
[29]
Halac G., Delil S., Zafer D., et al.: Compatibility of MRI and FDGPET
findings with histopathological results in patients with focal cortical
dysplasia. Seizure 2017; 45: 80–86.
[30]
Mellerio C., Labeyrie M.A., Chassoux F., et al.: 3T MRI improves the
detection of transmantle sign in type 2 focal cortical dysplasia. Epilepsia
2014; 55: 117–122.
[31]
Eltze C.M., Chong W.K., Bhate S., et al.: Taylor-type Focal Cortical
Dysplasia in Infants: Some MRI Lesions Almost Disappear with
Maturation of Myelination. Epilepsia 2005; 46: 1988–1992.
[32]
Bouet R., Mauguiere F., Dalingault S., et al.: The relationship between
morphological lesion, magnetic source imaging and intracranial stereo-
electroencephalography in focal cortical dysplasia. Neuroimage Clin
2017; 15: 71–79.
[33]
Pittau F., Dubeau F., Gotman J.: Contribution of EEG/fMRI to the definition
of the epileptic focus. Neurology 2012; 78: 1479–1487.
[34]
Thornton R., Vulliemoz S., Rodionov R., et al.: Epileptic networks in focal
cortical dysplasia revealed using electroencephalography – functional
magnetic resonance imaging. Ann Neurol 2011; 70: 822–837.
[35]
Nobili L., Cardinale F., Maliola U.: Taylor’s focal cortical dysplasia
increases the risk of sleep-related epilepsy. Epilepsia 2009; 50: 2599–
2604.
[36]
Chassoux F., Rodrigo S., Semah F., et al.: FDG-PET improves surgical
outcome in negative MRI Taylor-type focal cortical dysplasias. Neurology
2010; 75: 2168–2175.
[37]
Krsek P., Kudr M., Jahodova A., et al.: Localizing value of ictal SPECT
is comparable to MRI and EEG in children with focal cortical dysplasia.
Epilepsia 2013; 54: 351–358.
[38]
Ueda Y., Egawa K., Ito T., et al.: The presence of short and sharp MEG
spikes implies focal cortical dysplasia. Epilepsy 2015; 114: 141–146.
[39]
Ishii R., Canuet L., Ochi A., et al.: Spatially filtered magnetoencephalo
-
graphy to identify. Epilepsy res 2008; 81: 228–232.
[40]
Zhang B., McDaniel S.S., Rensing N.R., et al.: Vigabatrin inhibits seizures
and mTOR pathway activation in a mouse model of tuberous sclerosis
complex. PLoS one 2013; 8.
[41]
Devinsky O., Hopkins M. Weiner H. et al.: A Pilot Study To Evaluate
The Effects of Everolimus on Brain mTOR Activity and Cortical
Hyperexcitability in TSC and FCD. New York University School of
Medicine. Adres: http://clinicaltrials.gov/ct2/show/NCT02451696
[42]
Heung Dong K.: A Prospective, Randomized, Double-blind, Placebo-
controlled Cross Over Study Investigating the Anti-epileptic Efficacy of
Afinitor (Everolimus) in Patients With Refractory Seizures Who Have
Focal Cortical Dysplasia Type II (FCD II). Yonsei University. Adres: http://
clinicaltrials.gov/ct2/show/NCT03198949
[43]
Jung D.E., Kang H.C., Kim H.D.: Long-Term Outcome of the Ketogenic
Diet for Intractable Childhood Epilepsy With Focal Malformation of
Cortical Development. Pediatrics 2008; 122: 2008–2012.
[44]
Cross H. et al.: A Randomised Controlled Trial to Compare Seizure
Remission Outcome Following Resective Surgery With or Without Prior
Treatment With Ketogenic Diet in Children With Epilepsy the Result of
Focal Cortical Dysplasia Type II. Adres: http://www.edible.org.uk
[45]
Mrelashvili A., Witte R.J., Wirrell E., et al.: Seizure Freedom in Children
With Pathology-Confirmed Focal Cortical Dysplasia. Pediatr Neurol 2015;
53: 513–518.
Scholar Google
PubMed